Cryoport(US:CYRX)2022-02-28 22:24Clinical Trials and Therapies - Cryoport supported 602 clinical trials and eight commercial therapies by the end of fiscal year 2021, with expectations of up to 19 Biologic License Applications (BLAs) and Marketing Authorization Applications (MAAs) submissions in 2022[14]. - As of December 31, 2021, Cryoport supported over 602 clinical trials in regenerative medicine and logged over 500,000 shipments to over 100 countries in the last 12 months[32]. - Cryoport is now supporting eight commercially approved products in the regenerative medicine space, including therapies from Novartis and Bristol Myers Squibb[32]. - Cryoport supports 602 clinical trials and 8 commercial programs in the cell and gene therapy market, establishing itself as a premier provider of supply chain solutions[56]. Customer Base and Global Presence - The company serves over 3,000 customers across 15 countries and 33 locations, employing more than 850 personnel[13]. - The acquisition of CRYOPDP in October 2020 expanded Cryoport's network to 33 facilities in 15 countries, enhancing logistics capabilities and client proximity[35]. - As of December 31, 2021, Cryoport leased or owned 33 total sites across the Americas, EMEA, and APAC regions, enhancing its global logistics capabilities[64]. - The geographical revenue breakdown for 2021 shows 54.0% from the Americas, 26.7% from EMEA, and 19.3% from APAC, indicating a shift in market focus[70]. Supply Chain Solutions - Cryoport's advanced supply chain platform includes the Cryoportal® and CRYOPDP UnITy platforms, which provide near real-time shipment tracking and regulatory compliance[19]. - Cryoport's Chain of Compliance® solutions ensure full traceability and minimize risks for clients' new biologics and therapies[16]. - Cryoport's solutions are designed to support various therapy types, including cell-based autologous immunotherapy, allogeneic therapies, and gene therapies, ensuring compliance and safety throughout the supply chain[21][23][24]. - Cryoport's Cryoportal® logistics management platform provides 24/7 monitoring of shipments and predictive analysis, ensuring high service reliability[33]. Product Development and Innovation - The company is launching the Cryoport ELITE™ product line, which includes the Cryosphere™ and an ELITE™-80°C shipper, aimed at supporting cell and gene therapy distribution[20]. - The Cryosphere™, a new cryogenic shipper, is expected to launch in the first half of 2022, designed to stabilize payloads and enhance user experience[41]. - The Cryoport ELITE™ -80°C Gene Therapy Shipper is set to launch in the first half of 2022, featuring advanced temperature management and data collection systems[87]. - Cryoport's MVE Fusion® Cryogenic Freezers are the first self-sustaining cryogenic freezers, eliminating the need for ongoing liquid nitrogen supply[89]. Environmental and Sustainability Initiatives - The company has initiated a formal internal evaluation of its ESG policies since 2020, with a focus on developing a comprehensive sustainability program[115]. - In 2021, the Houston plant consumed 4,489,987 kWh of electricity, and by utilizing GHG emissions-free electricity, the emission of 1,440,257 pounds of GHGs was avoided, equivalent to removing 242 passenger vehicles driven for one year[124]. - Cryoport's use of liquid nitrogen freezers prevented the consumption of 1,883,136 kWh of electricity in 2021, avoiding 1,725,871 pounds of GHG emissions compared to standard mechanical freezers[126]. - The MVE Biological Solutions production facility's fusion freezer units saved 139,424,817 kWh of energy annually, equivalent to avoiding 123,444,781 pounds of GHG emissions, or the emissions from 21,489 passenger vehicles driven for one year[143]. Financial Overview - The estimated fair value of the Convertible Senior Notes was $345.4 million as of December 31, 2021[377]. - As of December 31, 2021, the company had foreign-denominated cash and cash equivalents totaling $19.3 million[379]. - A 5%, 10%, and 20% adverse change in foreign exchange would result in declines of $1.0 million, $1.9 million, and $3.9 million, respectively, in "Accumulated other comprehensive income (loss)"[379]. - A 5%, 10%, and 20% adverse change in foreign exchange for these balances would lead to losses of $3.9 million, $7.8 million, and $15.7 million, respectively, recorded in "Accumulated other comprehensive income (loss)"[380]. Workforce and Diversity - As of December 31, 2021, the company employed 847 individuals, an increase of over 220 employees since December 31, 2020, to support global growth[160]. - As of December 2021, women represented approximately 30% of all employees, with 18% in management and 8% in director roles, indicating a need for improved gender diversity in senior leadership[134]. Compliance and Quality Standards - Cryoport's manufacturing operations are ISO 13485 certified, ensuring compliance with medical manufacturing standards and regular audits by authorized authorities[108]. - Cryoport's products comply with various international safety and quality standards, including ISO 13485 and IEC 60601-1, ensuring the safety and efficacy of its temperature-controlled supply chain solutions[138]. - Cryoport's Chain of Compliance™ platform aligns with ISO 21973 guidance, ensuring high standards for the transportation of cells for therapeutic use[56]. Strategic Growth and Market Position - The company emphasizes its competitive advantage through its integrated platform of services and technology-driven supply-chain solutions, which are unmatched in the industry[28]. - Cryoport aims to expand its global presence and capabilities through targeted acquisitions and strategic alliances in the life sciences sector[51]. - The company anticipates hiring additional personnel as required to implement its global growth strategy[160]. - Cryoport plans to enhance its sales and marketing initiatives globally, focusing on the Americas, EMEA, and APAC regions, by hiring additional resources and expanding its distributor network[82].